Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 5, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	45	31	32	21	54	120
Market Cap Growth	42.17%	-2.84%	56.90%	-62.03%	-55.00%	250.73%
Enterprise Value	29	20	7	-10	8	92
Last Close Price	3.22	2.28	3.42	2.76	7.32	28.80
PS Ratio	-	-	-	-	-	612.61
PB Ratio	0.72	0.47	0.52	0.30	0.50	2.16
P/TBV Ratio	3.36	1.81	2.58	1.10	2.12	2.16
EV/Sales Ratio	-	-	-	-	-	470.71
Debt / Equity Ratio	-	-	-	0.01	0.00	0.00
Asset Turnover	-	-	-	-	-	0.01
Quick Ratio	13.56	11.53	14.09	8.41	13.56	38.80
Current Ratio	13.89	11.77	14.26	8.59	13.89	39.50
Return on Equity (ROE)	-13.15%	-14.91%	-19.82%	-48.15%	-11.98%	-57.33%
Return on Assets (ROA)	-11.85%	-14.35%	-9.25%	-10.96%	-7.94%	-15.70%
Return on Capital (ROIC)	-13.14%	-16.24%	-10.83%	-12.86%	-9.23%	-19.45%
Return on Capital Employed (ROCE)	-19.10%	-23.80%	-15.70%	-24.00%	-9.70%	-17.60%
Earnings Yield	-17.19%	-30.59%	-39.92%	-206.80%	-18.17%	-16.39%
FCF Yield	-26.41%	-47.65%	-38.38%	-77.64%	-31.90%	-11.98%
Buyback Yield / Dilution	-23.94%	-26.85%	-28.16%	-21.09%	-148.46%	-40.25%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q